PortalPublikationenLong-term survival of an adolescent glioblastoma patient und...

Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling

Standard

Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling. / Kresbach, Catena; Bronsema, Annika; Guerreiro, Helena; Rutkowski, Stefan; Schüller, Ulrich; Winkler, Beate.

in: CHILD NERV SYST, Jahrgang 38, Nr. 2, 02.2022, S. 479-483.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kresbach, C, Bronsema, A, Guerreiro, H, Rutkowski, S, Schüller, U & Winkler, B 2022, 'Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling', CHILD NERV SYST, Jg. 38, Nr. 2, S. 479-483. https://doi.org/10.1007/s00381-021-05278-6

APA

Kresbach, C., Bronsema, A., Guerreiro, H., Rutkowski, S., Schüller, U., & Winkler, B. (2022). Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling. CHILD NERV SYST, 38(2), 479-483. https://doi.org/10.1007/s00381-021-05278-6

Vancouver

Kresbach C, Bronsema A, Guerreiro H, Rutkowski S, Schüller U, Winkler B. Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling. CHILD NERV SYST. 2022 Feb;38(2):479-483. https://doi.org/10.1007/s00381-021-05278-6

Bibtex

@article{f9de8b8fbbb441a1bc927a688dd674a9,
title = "Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling",
abstract = "Glioblastoma (GBM) is an exceptionally aggressive brain tumor with a dismal prognosis, demanding fast and precise classification as a base for patient-specific treatment strategies. Here, we report on an adolescent patient with a histologically bona fide GBM that shows a molecular methylation profile suggesting a low-grade glioma-like subgroup. Despite an early relapse, intolerance of temozolomide, and change of treatment strategy to vinblastine and valproic acid (VPA), the patient is now in good clinical condition after more than 5 years since initial diagnosis. This case stresses the merit of methylation array data for clinical prognosis and treatment planning.",
author = "Catena Kresbach and Annika Bronsema and Helena Guerreiro and Stefan Rutkowski and Ulrich Sch{\"u}ller and Beate Winkler",
note = "{\textcopyright} 2021. The Author(s).",
year = "2022",
month = feb,
doi = "10.1007/s00381-021-05278-6",
language = "English",
volume = "38",
pages = "479--483",
journal = "CHILD NERV SYST",
issn = "0256-7040",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Long-term survival of an adolescent glioblastoma patient under treatment with vinblastine and valproic acid illustrates importance of methylation profiling

AU - Kresbach, Catena

AU - Bronsema, Annika

AU - Guerreiro, Helena

AU - Rutkowski, Stefan

AU - Schüller, Ulrich

AU - Winkler, Beate

N1 - © 2021. The Author(s).

PY - 2022/2

Y1 - 2022/2

N2 - Glioblastoma (GBM) is an exceptionally aggressive brain tumor with a dismal prognosis, demanding fast and precise classification as a base for patient-specific treatment strategies. Here, we report on an adolescent patient with a histologically bona fide GBM that shows a molecular methylation profile suggesting a low-grade glioma-like subgroup. Despite an early relapse, intolerance of temozolomide, and change of treatment strategy to vinblastine and valproic acid (VPA), the patient is now in good clinical condition after more than 5 years since initial diagnosis. This case stresses the merit of methylation array data for clinical prognosis and treatment planning.

AB - Glioblastoma (GBM) is an exceptionally aggressive brain tumor with a dismal prognosis, demanding fast and precise classification as a base for patient-specific treatment strategies. Here, we report on an adolescent patient with a histologically bona fide GBM that shows a molecular methylation profile suggesting a low-grade glioma-like subgroup. Despite an early relapse, intolerance of temozolomide, and change of treatment strategy to vinblastine and valproic acid (VPA), the patient is now in good clinical condition after more than 5 years since initial diagnosis. This case stresses the merit of methylation array data for clinical prognosis and treatment planning.

U2 - 10.1007/s00381-021-05278-6

DO - 10.1007/s00381-021-05278-6

M3 - SCORING: Journal article

C2 - 34309720

VL - 38

SP - 479

EP - 483

JO - CHILD NERV SYST

JF - CHILD NERV SYST

SN - 0256-7040

IS - 2

ER -